Fortis Health.

INR
830.10
18.7 (2.3%)
BSENSE

Mar 25

BSE+NSE Vol: 17.82 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

17.82 lacs (-14.84%) Volume

Shareholding (Dec 2025)

FII

27.84%

Held by 710 FIIs

DII

1.67%

Held by 83 DIIs

Promoter

31.17%

how big is Fortis Health.?

06-Jun-2025

As of Jun 06, Fortis Healthcare Ltd has a market capitalization of 57,671.25 Cr, with recent net sales of 7,782.75 Cr and net profit of 774.21 Cr over the last four quarters. Shareholder's funds are 7,662.90 Cr, and total assets amount to 12,971.37 Cr as of Mar 2024.

Market Cap: As of Jun 06, Fortis Healthcare Ltd has a market capitalization of 57,671.25 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the sum of Net Sales is 7,782.75 Cr, and the sum of Net Profit is 774.21 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar 2024. The Shareholder's Funds are reported at 7,662.90 Cr, and the Total Assets amount to 12,971.37 Cr.

View full answer

When is the next results date for Fortis Health.?

06-Jun-2025

No Upcoming Board Meetings

Has Fortis Health. declared dividend?

06-Jun-2025

Fortis Healthcare Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of July 24, 2024. The dividend yield is 0.13%, and the company has shown significant price appreciation and total returns across various periods.

Fortis Healthcare Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 24 Jul 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 6.7%, the dividend return was 0%, resulting in a total return of 6.7%.<BR><BR>Over the past year, the price return was 71.16%, the dividend return was 0.21%, leading to a total return of 71.37%.<BR><BR>In the 2-year period, the price return was 170.94%, with a dividend return of 0.65%, culminating in a total return of 171.59%.<BR><BR>For the 3-year period, the price return was 214.91%, the dividend return was 0.87%, resulting in a total return of 215.78%.<BR><BR>In the 4-year period, the price return was 236.71%, with a dividend return of 0.84%, leading to a total return of 237.55%.<BR><BR>Over the last 5 years, the price return was 548.54%, the dividend return was 1.56%, resulting in a total return of 550.1%.<BR><BR>Overall, Fortis Healthcare Ltd has declared a dividend while also demonstrating significant price appreciation over the years, with total returns reflecting strong performance across all periods. The dividend yield remains modest, indicating that the company is focusing on growth alongside returning value to shareholders.

View full answer

Who are the peers of the Fortis Health.?

03-Jun-2025

Fortis Health's peers include Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Fortis Health has good management risk and growth, with a 1-year return of 60.01%, lower than Krishna Institute's 85.47%.

Peers: The peers of Fortis Health are Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, and Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, Jupiter Life Lin, and the rest. Good management risk is found at Fortis Health. Average management risk is present at Aster DM Health. Excellent growth is noted at Max Healthcare and Apollo Hospitals, while good growth is observed at Fortis Health, Narayana Hrudaya, and Dr Agarwal's Hea. Below average growth is seen at Aster DM Health and Krishna Institu, and the rest. Excellent capital structure is noted at Max Healthcare, Global Health, Krishna Institu, and the rest, while good capital structure is found at Fortis Health, Narayana Hrudaya, Rainbow Child, and Dr Agarwal's Hea. Average capital structure is present at Apollo Hospitals and Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu at 85.47%, while the lowest is Dr Agarwal's Hea with no available data. Fortis Health's 1-year return is 60.01%, which is significantly higher than Dr Agarwal's Hea but lower than Krishna Institu. Additionally, Aster DM Health and Dr Agarwal's Hea have negative six-month returns.

View full answer

Who are in the management team of Fortis Health.?

16-Jul-2025

As of March 2023, the management team of Fortis Health includes Ashutosh Raghuvanshi (Managing Director & CEO), Ravi Rajagopal (Chairman), and several independent and non-executive directors, totaling 12 members with diverse expertise.

As of March 2023, the management team of Fortis Health includes the following members:<BR><BR>1. Suvalaxmi Chakraborty - Independent Director<BR>2. Ravi Rajagopal - Chairman & Independent Director<BR>3. Indrajit Banerjee - Independent Director<BR>4. Ashutosh Raghuvanshi - Managing Director & CEO<BR>5. Sim Heng Joo Joe - Non Executive Director<BR>6. Shailaja Chandra - Independent Director<BR>7. Dilip Kadambi - Non Executive Director<BR>8. Joerg Ayrla - Non Executive Director<BR>9. Murlee Manohar Jain - Company Secretary & Compliance Officer<BR>10. Tomo Nagahiro - Non Executive Director<BR>11. Mehmet Ali Aydinlar - Non Executive Director<BR>12. Lim Tsin Lin - Non Executive Director<BR><BR>This diverse team brings a range of expertise and leadership to Fortis Health.

View full answer

What does Fortis Health. do?

17-Jul-2025

Fortis Healthcare Ltd is a leading large-cap healthcare services provider in India, with recent net sales of ₹20,072 Cr and a net profit of ₹1,839 Cr as of March 2025. The company operates hospitals and has a market capitalization of ₹60,744 Cr.

Overview:<BR>Fortis Healthcare Ltd is one of the largest healthcare services providers in India, operating in the hospital industry and classified as a large-cap company.<BR><BR>History:<BR>Fortis Healthcare Ltd was incorporated in an unspecified year and has maintained its status as a leading healthcare provider. The latest quarterly results reported are for March 2025, showing significant sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 20,072 Cr (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 1,839 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 60,744 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 72.00<BR>Industry P/E: 59<BR>Dividend Yield: 0.12%<BR>Debt-Equity: 0.22<BR>Return on Equity: 9.41%<BR>Price to Book: 6.78<BR><BR>Contact Details:<BR>Address: Fortis Hospital Sector-62, Phase-VIII Mohali Punjab : 160062<BR>Phone: 91-172-5096001<BR>Email: secretarial@fortishealthcare.com<BR>Website: http://www.fortishealthcare.com

View full answer

Who are the top shareholders of the Fortis Health.?

17-Jul-2025

The top shareholders of Fortis Health include promoters holding 31.17%, mutual funds with 25.77%, and foreign institutional investors (FIIs) at 27.4%. HDFC Mutual Fund is the largest public shareholder, owning 6%, while individual investors hold 10.22%.

The top shareholders of Fortis Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Northern Tk Venture Pte. Ltd. holding the highest stake at 31.17%. Mutual funds collectively hold 25.77% of the shares through 27 schemes, while FIIs own 27.4% of the company through 389 different investors. The highest public shareholder is HDFC Mutual Fund, specifically through the HDFC S&P BSE 500 ETF, which holds 6%. Additionally, individual investors account for 10.22% of the shareholding.

View full answer

Are Fortis Health. latest results good or bad?

07-Aug-2025

Fortis Healthcare's latest results are positive, with a record Profit After Tax of Rs 250.67 crore and net sales of Rs 2,166.72 crore, indicating strong growth. However, rising interest expenses and an increased debt-equity ratio suggest potential liquidity concerns, leading to a 'Hold' rating from MarketsMOJO.

Fortis Healthcare's latest results for the quarter ending June 2025 are quite positive. The company reported a Profit After Tax (PAT) of Rs 250.67 crore, which is the highest in the last five quarters, indicating strong growth. Net sales also reached a peak of Rs 2,166.72 crore, reflecting a solid upward trend with a quarter-on-quarter growth of 7.95%.<BR><BR>Additionally, the operating profit (PBDIT) was recorded at Rs 490.67 crore, also the highest in five quarters, with an operating profit margin of 22.65%, showcasing improved operational efficiency. The Profit Before Tax (PBT) increased significantly by 25.3% compared to the average of the previous four quarters.<BR><BR>However, there are some challenges to consider. Interest expenses have risen sharply to Rs 137.13 crore, a 68.09% increase, which suggests higher borrowing costs. The debt-equity ratio has also increased to 0.28 times, indicating greater leverage and potential liquidity concerns.<BR><BR>Overall, while the financial performance shows strong growth and efficiency improvements, the rising interest expenses and increased leverage are factors that need to be monitored. The stock is currently rated as a 'Hold' by MarketsMOJO, reflecting a cautious outlook amidst these challenges.

View full answer

Is Fortis Health. technically bullish or bearish?

06-Nov-2025

As of November 4, 2025, Fortis Health's technical trend is mildly bullish, supported by positive MACD and moving averages, though caution is advised due to mixed signals from the weekly KST and Dow Theory.

As of 4 November 2025, the technical trend for Fortis Health has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the weekly KST is mildly bearish, and the Dow Theory shows a mildly bearish signal on the weekly timeframe, suggesting some caution. The Bollinger Bands indicate a mildly bullish outlook on both weekly and monthly timeframes. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from KST and Dow Theory.

View full answer

How has been the historical performance of Fortis Health.?

12-Nov-2025

Fortis Health has shown consistent growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 4,469.36 Cr to 7,782.75 Cr and profit after tax rising from a loss of 588.12 Cr to 797.86 Cr. The company has demonstrated a strong recovery, with significant improvements in operating profit and cash flow during this period.

Answer:<BR>The historical performance of Fortis Health shows a consistent growth trajectory in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Fortis Health's net sales have steadily increased from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025, reflecting a robust growth trend. The total operating income followed a similar pattern, rising from 4,469.36 Cr to 7,782.75 Cr during the same period. The operating profit (PBDIT) also demonstrated significant improvement, increasing from 317.62 Cr in March 2019 to 1,654.88 Cr in March 2025, with an operating profit margin that improved from 5.04% to 20.4%. Profit before tax reached 995.52 Cr in March 2025, up from a loss of 474.51 Cr in March 2019, while profit after tax rose to 797.86 Cr from a loss of 588.12 Cr in March 2019. The consolidated net profit has shown a positive trend, increasing from -298.93 Cr in March 2019 to 774.21 Cr in March 2025. The company's total assets have grown from 10,954.94 Cr in March 2020 to 13,376.98 Cr in March 2025, and total liabilities increased from 10,954.94 Cr to 13,376.98 Cr during the same period. Cash flow from operating activities improved significantly, reaching 1,423.00 Cr in March 2025 compared to 171.00 Cr in March 2020. Overall, Fortis Health has demonstrated a strong recovery and growth in financial performance over the years.

View full answer

How has been the historical performance of Fortis Health.?

13-Nov-2025

Fortis Health has shown consistent growth in net sales and profitability, with net sales increasing from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025, and profit after tax improving from a loss of 588.12 Cr to a profit of 797.86 Cr during the same period. The company's financial performance reflects a positive growth trajectory with rising revenues and operating profits.

Answer:<BR>The historical performance of Fortis Health shows a consistent growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Fortis Health has demonstrated a steady increase in net sales, rising from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025. The total operating income has followed a similar upward trajectory, reaching 7,782.75 Cr in March 2025, compared to 4,469.36 Cr in March 2019. The company has also improved its operating profit (PBDIT), which increased from 317.62 Cr in March 2019 to 1,654.88 Cr in March 2025, reflecting an operating profit margin of 20.4% in the latest fiscal year. Profit before tax has shown a positive trend, moving from a loss of 474.51 Cr in March 2019 to a profit of 995.52 Cr in March 2025. Consequently, profit after tax has also improved significantly, from a loss of 588.12 Cr in March 2019 to a profit of 797.86 Cr in March 2025. The company's total assets have increased from 10,954.94 Cr in March 2020 to 13,376.98 Cr in March 2025, while total liabilities have also risen, indicating a growing business scale. Cash flow from operating activities has improved, reaching 1,423.00 Cr in March 2025, although the company experienced a net cash outflow of 69.00 Cr in the same period. Overall, Fortis Health's financial performance reflects a positive growth trajectory with increasing revenues and profitability over the years.

View full answer

Is Fortis Health. overvalued or undervalued?

05-Dec-2025

As of December 4, 2025, Fortis Health is considered expensive and overvalued with a PE ratio of 66.42, higher than its peers, despite a strong YTD return of 23.12% compared to the Sensex's 9.12%.

As of 4 December 2025, the valuation grade for Fortis Health has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 66.42, an EV to EBITDA ratio of 37.50, and a Price to Book Value of 7.09. <BR><BR>In comparison to its peers, Fortis Health's PE ratio is higher than Apollo Hospitals at 61.81 and Narayana Hrudaya at 46.47, both of which are also categorized as expensive. The company's recent stock performance shows a YTD return of 23.12%, significantly outperforming the Sensex's return of 9.12% during the same period, which may indicate strong market interest despite its overvaluation.

View full answer

Should I buy, sell or hold Fortis Healthcare Ltd?

06-Mar-2026

Why is Fortis Healthcare Ltd falling/rising?

18-Mar-2026

As of 17-Mar, Fortis Healthcare Ltd's stock price is rising to 818.55, following a trend reversal after four days of decline, with increased investor participation and strong fundamentals supporting its long-term growth potential. Despite recent gains, the stock remains below its moving averages, indicating a possible broader downtrend.

As of 17-Mar, Fortis Healthcare Ltd's stock price is rising, currently at 818.55, which reflects an increase of 9.9 (1.22%). This upward movement follows a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, the stock outperformed its sector by 0.67% today and reached an intraday high of Rs 825.8, marking a 2.12% increase.<BR><BR>Investor participation has also risen, with a delivery volume of 12.82 lacs on 16 March, which is a significant increase of 49.51% compared to the five-day average. This suggests growing interest among investors, contributing to the stock's price rise.<BR><BR>Despite the recent gains, it is important to note that Fortis Healthcare is trading below its moving averages across various time frames, indicating that it may still be in a broader downtrend. However, the company's strong fundamentals, such as a low Debt to EBITDA ratio of 0.91 times and high institutional holdings at 57.17%, support its long-term growth potential. The stock has also demonstrated consistent returns over the past three years, outperforming the BSE500.<BR><BR>In summary, the combination of a trend reversal, increased investor participation, and strong fundamentals are key factors contributing to the rise in Fortis Healthcare Ltd's stock price.

View full answer

Why is Fortis Healthcare Ltd falling/rising?

19-Mar-2026

As of 18-Mar, Fortis Healthcare Ltd's stock price is rising to 843.50, with a 2.85% increase and strong investor interest reflected in a 46.75% rise in delivery volume. The company shows solid fundamentals, including a low Debt to EBITDA ratio and high institutional holdings, contributing to positive market sentiment.

As of 18-Mar, Fortis Healthcare Ltd's stock price is rising, currently at 843.50, reflecting an increase of 23.35 (2.85%). The stock has shown a positive performance today, outperforming its sector by 1.55%, and has gained consecutively over the last two days, achieving a total return of 4.31% in this period. Additionally, the stock reached an intraday high of Rs 850.6, which is a 3.71% increase.<BR><BR>Investor participation has also risen, with delivery volume on 17 March increasing by 46.75% compared to the five-day average, indicating growing interest in the stock. Furthermore, the company demonstrates strong fundamentals, including a low Debt to EBITDA ratio of 0.91 times and a healthy long-term growth rate in operating profit of 115.19% annually. The high institutional holdings at 57.17% suggest confidence from larger investors, who typically have more resources to analyze the company's fundamentals.<BR><BR>Despite some negative indicators, such as a low Operating Profit to Interest ratio and a high Debt-Equity ratio, the overall performance metrics and recent trading activity indicate a positive sentiment surrounding Fortis Healthcare Ltd, contributing to its rising stock price.

View full answer

Why is Fortis Healthcare Ltd falling/rising?

20-Mar-2026

As of 19-Mar, Fortis Healthcare Ltd's stock price is at 823.80, down 2.58% after a trend reversal. The stock has underperformed recently, with a year-to-date decline of 6.76%, despite a strong annual return of 34.67%.

As of 19-Mar, Fortis Healthcare Ltd's stock price is falling, currently at 823.80, which reflects a decrease of 21.85 points or 2.58%. This decline follows a trend reversal after two consecutive days of gains. The stock has also touched an intraday low of Rs 812.3, indicating a significant drop of 3.94% during the trading day.<BR><BR>In terms of performance relative to the market, the stock has underperformed in the short term, with a 1-week decline of 4.24% compared to the Sensex's drop of 2.40%. Over the past month, Fortis Healthcare has decreased by 9.13%, while the Sensex fell by 10.05%. Year-to-date, the stock is down 6.76%, although it has shown strong performance over the past year with a return of 34.67%, significantly outperforming the Sensex, which is down 1.65% in the same period.<BR><BR>The stock's current performance is also influenced by broader sector trends, as the Hospital & Healthcare Services sector has fallen by 2.63%. Additionally, Fortis Healthcare is trading below its moving averages across various time frames, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 16.05% against the 5-day average, the overall market sentiment appears negative.<BR><BR>Financially, while the company has a strong ability to service debt and healthy long-term growth, it faces challenges such as a low operating profit to interest ratio and a high debt-equity ratio. These factors contribute to a perception of expensive valuation, which may deter investors and lead to the stock's decline.

View full answer

Why is Fortis Healthcare Ltd falling/rising?

20-Mar-2026

As of 20-Mar, Fortis Healthcare Ltd's stock price is rising to 827.80, driven by strong debt servicing ability, healthy long-term growth, and high institutional holdings. Despite trading below moving averages, increased investor participation and outperformance against the sector support its upward trend.

As of 20-Mar, Fortis Healthcare Ltd's stock price is rising, currently at 827.80, with a change of 8.3 (1.01%) upwards. This rise can be attributed to several factors. Firstly, the stock has shown a strong ability to service debt, indicated by a low Debt to EBITDA ratio of 0.91 times, which suggests financial stability. Additionally, the company has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 115.19%. <BR><BR>Moreover, the stock has high institutional holdings at 57.17%, which often indicates confidence from sophisticated investors who can analyze company fundamentals more effectively than retail investors. The stock has also consistently outperformed the BSE500 over the last three years, generating a return of 31.92% in the past year, despite a challenging market environment where the Sensex has declined by 2.38%.<BR><BR>Today's performance shows that Fortis Healthcare has outperformed its sector by 0.45%, and there has been a notable increase in investor participation, with delivery volume rising by 21.79% compared to the 5-day average. However, it is important to note that the stock is currently trading below its moving averages across various time frames, indicating some potential concerns about its short-term performance. <BR><BR>Overall, the combination of strong institutional support, healthy growth metrics, and increased trading activity contributes to the stock's upward movement.

View full answer

Why is Fortis Healthcare Ltd falling/rising?

24-Mar-2026

As of 23-Mar, Fortis Healthcare Ltd's stock price is falling, currently at Rs 792.65, reflecting a decrease of 3.51%. The stock is underperforming its sector and trading below key moving averages, indicating a bearish trend amid negative returns and waning investor participation.

As of 23-Mar, Fortis Healthcare Ltd's stock price is falling, currently at Rs 792.65, which reflects a decrease of Rs 28.85 or 3.51%. This decline is evident in the stock's performance today, where it underperformed its sector by 1.11% and reached an intraday low of Rs 780, marking a drop of 5.05%. The stock is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of broader market performance, the stock has shown negative returns over various periods, including a 1-month decline of 13.80% compared to a 12.72% drop in the Sensex. Additionally, the year-to-date performance shows a decrease of 10.29%, while the sector itself, Hospital & Healthcare Services, has fallen by 2.37%. <BR><BR>Investor participation appears to be waning, as evidenced by a significant drop in delivery volume, which fell by 18.03% against the 5-day average. Despite the company's strong fundamentals, such as a low Debt to EBITDA ratio and high institutional holdings, the stock's current valuation metrics, including a high Debt-Equity ratio and low Operating Profit to Interest ratio, suggest underlying concerns that may be contributing to the stock's decline. Overall, these factors collectively indicate why Fortis Healthcare Ltd's stock is currently falling.

View full answer

Why is Fortis Healthcare Ltd falling/rising?

25-Mar-2026

As of 24-Mar, Fortis Healthcare Ltd's stock price is rising to 811.05, reflecting a 1.44% increase. Strong fundamentals, including a low Debt to EBITDA ratio and consistent long-term growth, support this upward movement, despite trading below moving averages and declining investor participation.

As of 24-Mar, Fortis Healthcare Ltd's stock price is rising, currently at 811.05, reflecting an increase of 11.55 (1.44%). The stock opened with a gain of 2.57% today and reached an intraday high of Rs 820.05. This upward movement is occurring despite the stock's recent underperformance compared to its sector, where it lagged by 0.91%. <BR><BR>The company's strong fundamentals contribute to this positive price movement. Fortis Healthcare has a low Debt to EBITDA ratio of 0.91 times, indicating a strong ability to service its debt. Additionally, the company has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 115.19%. The stock has also shown consistent returns over the past three years, outperforming the BSE500 index in each of the last three annual periods, with a notable 24.07% return in the last year.<BR><BR>However, it is essential to note that the stock is trading below its moving averages across various time frames, which could indicate underlying weaknesses. Furthermore, there has been a decline in investor participation, with delivery volume falling by 4.86% against the five-day average. Despite these factors, the high institutional holdings at 57.17% suggest that knowledgeable investors continue to support the stock, which may contribute to its current rise.

View full answer

Why is Fortis Healthcare Ltd falling/rising?

26-Mar-2026

As of 25-Mar, Fortis Healthcare Ltd's stock price is rising to 831.90, reflecting a 2.57% increase due to strong fundamentals, increased investor interest, and positive sector performance. The stock has outperformed its sector and shows a notable annual return of 29.10%.

As of 25-Mar, Fortis Healthcare Ltd's stock price is rising, currently at 831.90, reflecting a change of 20.85 (2.57%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.3% today and has shown a consecutive gain over the last two days, accumulating a total return of 4.05% during this period. Additionally, the stock reached an intraday high of Rs 832.25, indicating positive momentum.<BR><BR>Investor participation has also increased, with delivery volume rising by 21.05% against the 5-day average, suggesting heightened interest in the stock. The broader Hospital & Healthcare Services sector has gained by 2.27%, contributing to the positive sentiment surrounding Fortis Healthcare.<BR><BR>Moreover, the company demonstrates strong fundamentals, including a low Debt to EBITDA ratio of 0.91 times, which indicates a strong ability to service its debt. The stock has consistently generated returns, with a notable 29.10% increase over the past year, outperforming the BSE500 index in each of the last three annual periods. High institutional holdings at 57.17% further support the stock's stability, as these investors typically have more resources to analyze the company's fundamentals.<BR><BR>In summary, the combination of recent price gains, increased investor participation, positive sector performance, and strong financial fundamentals are driving the rise in Fortis Healthcare Ltd's stock price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

  • OPERATING PROFIT TO INTEREST (Q) Lowest at 5.90 times
  • DEBT-EQUITY RATIO(HY) Highest at 0.34 times
  • DEBTORS TURNOVER RATIO(HY) Lowest at 8.29 times
2

With ROCE of 11.9, it has a Expensive valuation with a 5.4 Enterprise value to Capital Employed

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 62,409 Cr (Mid Cap)

stock-summary
P/E

62.00

stock-summary
Industry P/E

55

stock-summary
Dividend Yield

0.12%

stock-summary
Debt Equity

0.29

stock-summary
Return on Equity

10.68%

stock-summary
Price to Book

6.49

Revenue and Profits:
Net Sales:
2,265 Cr
(Quarterly Results - Dec 2025)
Net Profit:
194 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.12%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.04%
0%
-8.04%
6 Months
-12.12%
0%
-12.12%
1 Year
28.17%
0.15%
28.32%
2 Years
105.11%
0.46%
105.57%
3 Years
225.72%
1.17%
226.89%
4 Years
201.14%
1.10%
202.24%
5 Years
315.36%
1.42%
316.78%

Latest dividend: 1 per share ex-dividend date: Jul-25-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Fortis Healthcare Limited - Updates

05-Dec-2019 | Source : NSE

Fortis Healthcare Limited has informed the Exchange regarding 'Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI LODR")'.

Fortis Healthcare Limited - Change in Director(s)

27-Nov-2019 | Source : NSE

Fortis Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company.In compliance of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that Board of Directors of the Company has approved appointment of Mr. Sim Heng Joo Joe (DIN:08033111) ( Mr. Joe ) as an additional director (Non-Executive and Non-Independent) of the Company with immediate effect. He will hold the office up to the next Annual General Meeting and will be regularized subject to the approval of the shareholders. He is not related to any of the existing directors. Brief Profile of Mr. Joe is attached herewith.

Fortis Healthcare Limited - Press Release

18-Nov-2019 | Source : NSE

Fortis Healthcare Limited has informed the Exchange regarding a press release dated November 18, 2019, titled "Intimation under Regulation 30 Press Release".

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Fortis Healthcare Ltd has declared 10% dividend, ex-date: 25 Jul 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Fortis Healthcare Ltd has announced 2:5 rights issue, ex-date: 18 Aug 09

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
17.65%
EBIT Growth (5y)
115.19%
EBIT to Interest (avg)
5.98
Debt to EBITDA (avg)
1.45
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.72
Tax Ratio
23.25%
Dividend Payout Ratio
9.75%
Pledged Shares
0
Institutional Holding
57.17%
ROCE (avg)
9.81%
ROE (avg)
7.20%

Valuation key factors

Factor
Value
P/E Ratio
62
Industry P/E
55
Price to Book Value
6.66
EV to EBIT
42.08
EV to EBITDA
32.98
EV to Capital Employed
5.38
EV to Sales
7.48
PEG Ratio
2.24
Dividend Yield
0.12%
ROCE (Latest)
11.89%
ROE (Latest)
10.68%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 34 Schemes (24.22%)

FIIs

Held by 710 FIIs (27.84%)

Promoter with highest holding

Northern Tk Venture Pte. Ltd. (31.17%)

Highest Public shareholder

Hdfc Mutual Fund - Hdfc Pharma And Healthcare Fund (5.96%)

Individual Investors Holdings

10.14%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -2.85% vs 7.60% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -39.82% vs 23.68% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,265.01",
          "val2": "2,331.44",
          "chgp": "-2.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "505.65",
          "val2": "556.33",
          "chgp": "-9.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "85.74",
          "val2": "74.88",
          "chgp": "14.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-45.91",
          "val2": "23.53",
          "chgp": "-295.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "193.73",
          "val2": "321.92",
          "chgp": "-39.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.32%",
          "val2": "23.86%",
          "chgp": "-1.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 16.92% vs 12.25% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 70.03% vs 19.95% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,498.16",
          "val2": "3,847.29",
          "chgp": "16.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,047.00",
          "val2": "777.35",
          "chgp": "34.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "144.45",
          "val2": "71.70",
          "chgp": "101.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "36.16",
          "val2": "-59.57",
          "chgp": "160.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "582.20",
          "val2": "342.42",
          "chgp": "70.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.28%",
          "val2": "20.21%",
          "chgp": "3.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 17.10% vs 13.09% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 31.44% vs 40.50% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,763.17",
          "val2": "5,775.55",
          "chgp": "17.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,552.65",
          "val2": "1,152.47",
          "chgp": "34.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "230.19",
          "val2": "116.85",
          "chgp": "97.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.75",
          "val2": "-35.77",
          "chgp": "72.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "775.93",
          "val2": "590.32",
          "chgp": "31.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.96%",
          "val2": "19.95%",
          "chgp": "3.01%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 12.91% vs 9.45% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 29.28% vs 1.72% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,782.75",
          "val2": "6,892.92",
          "chgp": "12.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,587.94",
          "val2": "1,267.64",
          "chgp": "25.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "184.41",
          "val2": "130.95",
          "chgp": "40.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-89.34",
          "val2": "16.02",
          "chgp": "-657.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "774.21",
          "val2": "598.88",
          "chgp": "29.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.40%",
          "val2": "18.39%",
          "chgp": "2.01%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
2,265.01
2,331.44
-2.85%
Operating Profit (PBDIT) excl Other Income
505.65
556.33
-9.11%
Interest
85.74
74.88
14.50%
Exceptional Items
-45.91
23.53
-295.11%
Consolidate Net Profit
193.73
321.92
-39.82%
Operating Profit Margin (Excl OI)
22.32%
23.86%
-1.54%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -2.85% vs 7.60% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -39.82% vs 23.68% in Sep 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
4,498.16
3,847.29
16.92%
Operating Profit (PBDIT) excl Other Income
1,047.00
777.35
34.69%
Interest
144.45
71.70
101.46%
Exceptional Items
36.16
-59.57
160.70%
Consolidate Net Profit
582.20
342.42
70.03%
Operating Profit Margin (Excl OI)
23.28%
20.21%
3.07%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 16.92% vs 12.25% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 70.03% vs 19.95% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
6,763.17
5,775.55
17.10%
Operating Profit (PBDIT) excl Other Income
1,552.65
1,152.47
34.72%
Interest
230.19
116.85
97.00%
Exceptional Items
-9.75
-35.77
72.74%
Consolidate Net Profit
775.93
590.32
31.44%
Operating Profit Margin (Excl OI)
22.96%
19.95%
3.01%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 17.10% vs 13.09% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 31.44% vs 40.50% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
7,782.75
6,892.92
12.91%
Operating Profit (PBDIT) excl Other Income
1,587.94
1,267.64
25.27%
Interest
184.41
130.95
40.82%
Exceptional Items
-89.34
16.02
-657.68%
Consolidate Net Profit
774.21
598.88
29.28%
Operating Profit Margin (Excl OI)
20.40%
18.39%
2.01%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 12.91% vs 9.45% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 29.28% vs 1.72% in Mar 2024

stock-summaryCompany CV
About Fortis Healthcare Ltd stock-summary
stock-summary
Fortis Healthcare Ltd
Mid Cap
Hospital
Fortis Healthcare Limited (FHL) is one of the largest healthcare services providers in India with 27 hospitals, ~4,500 operational beds and over 426 diagnostics centres as of 31 March, 2023. The Company offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services to patients in areas such as cardiac care, orthopedics, neurosciences, oncology, renal care, gastroenterology and mother and child care.
Company Coordinates stock-summary
Company Details
Fortis Hospital Sector-62, Phase-VIII Mohali Punjab : 160062
stock-summary
Tel: 91-172-5096001
stock-summary
secretarial@fortishealthcare.com
Registrar Details
Karvy Computershare Pvt Ltd, Plot No 17-24 , Near Image Hospital,, Reliance Cybervilae,Vithalrao Nagar,, Madhapur, Hyderabad